Professional Documents
Culture Documents
Animal House Final Findings 18may10
Animal House Final Findings 18may10
May 2010
KIPDC
Disclaimer
The study is based on responses from suppliers and producers from the industry as well as secondary sources Frost & Sullivan does not take responsibility for any incorrect information supplied to us by manufacturers or users
Quantitative market information is based primarily on interviews and therefore is subject to fluctuation The information available in the public domain has also been taken into consideration and the same is used for the preliminary understanding of the project
No part of this document may be given, lent, resold, or disclosed to non-customers without written permission.
Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the permission of the publisher.
For information regarding permission, write to: Frost & Sullivan Unit No. 641/642, 4th Floor, Solitaire Corporate Park, Chakala, Andheri(E). Mumbai-400093, India.
May 2010
Confidential
KIPDC
Contents
PART I Identification of Existing Animal Houses in India and Understanding of their Business Models ........................................................................................................................................... 7 Ownership and Business Model of Animal Houses in India..................................................... 8 Analysis of Business Sponsors Recurring vs. New business .................................................... 9 Revenue Contribution ................................................................................................................11 New Business Pre-Clinical Services .........................................................................................15 Types of Animal Houses in India ............................................................................................... 17 Type of Studies ............................................................................................................................ 18 Number of Animal Houses in India........................................................................................... 25 Value and Volume of Study Conducted................................................................................ 26 Project Component and Infrastructure Requirements ......................................................... 27 Infrastructure Required for an Animal House ......................................................................... 27 Regulatory Compliance............................................................................................................ 36 Regulatory Requirements for an Animal House ..................................................................... 39 Environmental Impact of an Animal House............................................................................ 41 Gaps in Facilities as Perceived by Sponsors ........................................................................... 42 Importance of Bangalore as a Suitable Location for Animal House .................................. 44 Benefits of setting up facility in Special Economic Zones (SEZs) ......................................... 49 Type of projects that can be sourced in India but are not there presently ...................... 66 PART II Financial Viability Assessment comprising of CAPEX requirements and revenue estimation .................................................................................................................................... 69 Built-up Infrastructure Requirements .........................................................................................70 Equipments Requirement...........................................................................................................72 Land Area Requirement.............................................................................................................73
May 2010
Confidential
KIPDC
Operational Costs of an Animal House....................................................................................74 Capital Requirement and Cash Flow Estimation for an Animal House .............................. 76 Case Study 1: AAALAC Approvable Small Animal House.....................................................76 Case Study 2: GLP Approvable Small Animal House .............................................................78 Conclusion....................................................................................................................................80 PART III Land Requirement and Site Suitability Assessment for Setting up of an Animal House ...................................................................................................................................................... 81 Estimation of Land Estimation for setting up of Envisaged Project...................................... 82 Key Parameters for selection of a site for project.................................................................. 83 Cost Based Factors......................................................................................................................84 Broad Sensitivities for selection of Land....................................................................................87 Assessment of classification of project by pollution control board and bye laws / prerequisites for setting up animal houses.................................................................................... 88 Frost & Sullivan Recommendations.......................................................................................... 92 Go/ No-Go Decision ...................................................................................................................92 Proposed Animal House Model.................................................................................................92 Facility Infrastructure ...................................................................................................................93 Business Model .............................................................................................................................94 Suggested Ownership Model ....................................................................................................95 Land Requirement.......................................................................................................................96 Expenditure ..................................................................................................................................96 Annexure 1: Animal Types for an Animal House .................................................................... 97 Annexure 2: Products Offered by Animal Houses.................................................................. 99 Small Animals ...............................................................................................................................99 Large Animals ............................................................................................................................105 Annexure 3: India Pharmaceutical & Biotechnology Industry Overview ...................... 108 India Pharmaceutical Industry Overview............................................................................108
May 2010 Confidential 4
KIPDC
India Biotechnology Industry Overview...............................................................................109 India BioClusters........................................................................................................................ 110
May 2010
Confidential
KIPDC
List of figures
Figure 1: Animal House Ownership Figure 2: Business split Figure 3: Clientele Figure 4: Revenue Contribution by Client Types Figure 5: Pharmaceutical R&D Expenditure, 2008-2015 Figure 6: Percentage of R&D budget allocation towards CRO activities by Sponsors, 2009-2015 Figure 7: Preclinical Services CRO market revenue forecasts (India), 2009-2015 Figure 8: Types of Animal Houses Figure 9: Split of Animal Houses Figure 10: Flowchart for Animal disposal Figure 11: Regulatory Approval Process Figure 12: Number of life sciences companies in Karnataka Figure 13: Karnataka Industry segment Figure 14: Client Profiles Figure15: Clientele Figure16: Business procedure of getting orders and supplying animals Figure17: Clinical trials in India, 2008-2015 (e) Figure18: Clinical trials by phases in India, 2008-2015 (e) Figure19: Therapeutic split (Phase-wise) for the clinical trials in India Figure20: Typical Animal House setup in India
May 2010
Confidential
KIPDC
PART I Identification of Existing Animal Houses in India and Understanding of their Business Models
May 2010
Confidential
KIPDC
Ownership and Business Model of Animal Houses in India
Animal Houses are typically understood to be enclosures where animals are raised and/ or bred for the purpose of lab testing while ensuring animal comfort. Animal houses can be large enclosures housing large animals like buffaloes, cows, horses, to smaller establishments containing small mammals like mice, rats, guinea pigs, etc. In India animal houses are either owned privately (independent animal houses), by government organizations (stand-alone or as a PPP) or by Pharma companies. Some animal houses in India are owned privately. These independent animal houses have the objective of utilizing the animal house to breed and supply animals for studies, also in some cases the animal houses have study areas where toxicology or pharmacology studies can be performed for research studies. Government owned animal houses are typically alliances between the government and private organizations, like ACTREC. Such organizations are focused primarily on maintaining animal houses for study of diseases. They also supply their specific animal strains on requirement to other study centers, when required. Pharma companies and Clinical Research Organizations also have their own in-house animal areas, or vivariums, which are maintained for toxicology and / or pharmacology studies for their own studies, or for studies contracted to them. Figure 1: Animal House Ownership
Private
Government Associated
May 2010
Confidential
KIPDC
Analysis of Business Sponsors Recurring vs. New business
All multinational and domestic Pharma and biotech companies, along with Clinical research Organizations and Medical Colleges/ Government R & D labs/ Research centers, etc. need to perform some preclinical testing, safety trials and other routine molecule studies before establishing the safety and efficacy of any product. For the initial preclinical testing, in most cases where cell lines cannot be used, animal models are used. Due to this continual requirement, such facilities generally maintain their own animal houses and raise the animal strain depending upon their forthcoming needs. Sometimes, however when the need for animal models is unprecedented or there is inadequate stock, they need to go out for private vendors and buy animals from there. Nearly all multinational companies (MNC) who have R & D presence in India, have their own animal house for supply of animals for routine tests. Same is true with major CROs involved in Pre-clinical testing. In such cases, they raise only those animals which will be needed the most for experimentation purpose, while in case of privately owned animal house, they have to keep sizeable stock of all types of strains ready so as to supply to the client when ordered. Now since the cost of maintaining animal models as per the CPCSEA guidelines is costly and the animal lifespan for mice, rat, etc. is low11, it sometimes becomes practically difficult to run a private animal house with considerable profits. MNC companies generally need to establish standard results globally and are somewhat more involved into innovation products rather than Biosimilars or generics, hence they prefer sourcing animals from their own Certified and internationally accredited animal house facilities. So, MNC companies with presence in India limit their animal studies, or perform them within their premises. This is because of the very few animal house facilities which are certified and accredited at an international level. Indian Companies/ CROs, may have a preferred tie-up or repeat business with a particular privately-owned animal house and they may source animals from there on a periodic basis either to maintain their standard stock by buying standard breeding pairs or directly using the animals from the vendor for studies. That may again depend on the demand of animals used for the study.
Typically, the lifespan of a rat is 2 years, of which the mature age which can be used for most studies lasts 6-10 months
1
May 2010
Confidential
KIPDC
5%
95%
Repeat Clients
New clients
For an animal house, the business usually comes from a set of clients who rely on the quality of animals provided to them in the past. The animal house in that case becomes the preferred vendor and the client becomes a repeat client whose demand can be estimated by the animal house. Approximately 5% of the customers are new customers who reach the animal house either because a. they have started a new study type, for which they do not have existing animals, or b. because their preferred vendor is unable to supply them the complete animal lot size required
May 2010
Confidential
10
KIPDC
Figure 3: Clientelle
10%
90%
International Clients
Indian Clients
Since most animal houses in India are GLP certifiable, and do not have international accreditations, the scope of servicing MNC companies reduces. Also, Indian companies prefer to source their study materials from within India, which ensures easier follow up and feedback, as well as a faster turnaround time. As a result it can be seen that 90% of the existing clients of an animal house are Indian companies, while only 10% are MNC or international companies. As more animal houses gain international certifications, the ratio is expected to shift towards international clients.
Revenue Contribution
Animal houses supply animals and perform studies for pharmaceutical studies. For an Animal House facility the main clients can be categorised as 1. Pharma Companies 2. Biotech/Biopharma Companies 3. Pharmacy Colleges 4. Research Institutes 5. Hospitals
May 2010
Confidential
11
KIPDC
Figure 4: Revenue Contribution by Client Types
Presently the distribution of clients between the given client types are provided in figure 3 above. We expect the distribution to remain the same over the next few years, with Pharma companies increasing in the total contribution to the toplines of existing animal houses. Each of the client types are explained in details below.
Pharma Companies
For a typical independent Animal house facility majority of the clients are research driven pharmaceutical companies. These companies are the ones who focus on New Chemical Entity (NCE) research. Presently, almost 90-95% of these companies are local companies such as Dr. Reddys, Ranbaxy, Glenmark, Zydus Cadila etc. The remaining are MNC pharma companies who have an R&D division in India, companies such as Astra Zeneca, Bayer Schering etc. The requirements range from animals for their own studies, and also to a limited extent also involve the animal house in performing the study as well. This depends on the facility of the animal house, its accreditations and prior experience. Some of these companies require close to 1,000 animals (mice and rats) per month. Their demand annually is more or less constant as they have a pre-determined number of molecules in pipeline. This segment contribution is expected to increase over the next 5 years as these companies are investing more funds in their R&D activity. This was confirmed by a recent Frost & Sullivan survey of leading research driven Pharma companies in India. The R&D expenses of Pharma companies are a direct indication of their focus on NCE research, and hence their needs for studies to be performed for their new molecules.
May 2010
Confidential
12
KIPDC
Since local Indian Pharma companies are the main clients for animal houses, below is an analysis of the research budgets of come Indian companies.
Figure 5: Pharmaceutical R&D Expenditure, 2008-2015
Total Pharmaceutical R&D Expenditure, 2008 2015 (USD Million)
CAGR (2008(2008-2012):11%
500 400 300 200 100 0 2008 2009 2010 2011 2012 2013 2014 2015
The R&D expenses of local companies has been increasing consistently over the past few years (10% yoy) The growth in R&D budgets for 2009-10 would have been higher, however it was impacted by recession and companies focusing more on sales generation R&D expenses are expected to continue growth due to increased tax benefits as declared in India Fiscal Budget 2010 R&D expenses have grown by 11% in the year 2007 to 2008 and are expected to grow at a similar pace over the coming years, with Indian companies focusing on new drug development Apart from buying animals for studies, Pharma companies also outsource their studies to animal
houses which have facilities to perform such experiments. In such cases, we expect the financial allocation of Pharma companies to be a part of their outsourced research budgets. Below is an analysis of the outsourcing research allocation of Pharma companies, and our expected budget allocation over the next few years.
Figure 6: Percentage of R&D budget allocation towards CRO activities by Sponsors, 2009-2015
11 % - 20 %
41% - 60%
61% - 80%
36.36
May 2010
2012 Confidential
2015
13
KIPDC
In 2009 17% of Sponsor companies surveyed allocate less than 10% of their total R&D budget for CRO activities, 75% companies allocate about 11 to 20% towards CROs and 8% companies allocate 20 to 40% for CRO activities By 2012, 50% of Sponsor companies surveyed will allocate 11 to 20% of their total R&D budget for CRO activities, 41% companies allocate about 20 to 40% towards CROs and 8% companies allocate 40 to 60% for CRO activities. By 2015, 36% of Sponsor companies surveyed will allocate 11 to 20% of their total R&D budget for CRO activities, 27% companies allocate about 20 to 40% towards CROs and 36% companies allocate 40 to 60% for CRO activities. 90% of the companies that were surveyed said they would spend close to 20 to 60% of their R&D budgets on clinical research. These companies comprised all the MNCs such as Astra Zeneca, Bayer Schering Pharma and Key Local companies such as Dr. Reddys, Biocon, Piramal Life Sciences etc. The remaining 10% of the comprised of small and medium companies that were surveyed, these include companies such as Titan Pharmaceutical, Aristo Pharmaceuticals This year on year increase in allocation of funds toward CRO related activities is an indication of the increased NCE work that is expected to be undertaken by companies in India. Companies doing research on New Chemical Entities require Animals both for Basic Research and also for Preclinical Toxicology testing. This increased NCE research work will translate into good business opportunity for Animal House facilities
Biotech/Biopharma companies
They are the second biggest clients for Animal Houses. This segment comprises of Biopharmaceutical companies such as Biocon, Intas, Avesthagen etc, vaccine manufacturers such as Serum Institute, Shantha Biotech, Bharat Biotech etc and Contract Research Organizations such as Advinus, Syngene, Jai Research Foundation etc. The Biotech Industry which is seeing a lot of encouragement and support from both the central governments is expected to grow rapidly. Indian companies are gearing up for producing Biosimilar drugs which require substantial R&D investment. This will be translated into increased use of animals for both basic and toxicology research. This segments contribution is expected to grow from 22% to about 25% or more over the next 5 years. The companies that will contribute to this growth will be the Small and Medium Biotech companies, CROs are not expected to contribute significantly as they are self sufficient for their animal requirements and prefer importing the animals rather than sourcing locally.
May 2010
Confidential
14
KIPDC
Research Institutes and Universities
They contribute another significant chunk of clients. The contribution from this segment too is expected to remain the same of decline slightly as most institutes are self sustained for animals.
Hospitals
Hospitals are a smaller segment and require the animals for raising antiserum and polyclonal antibodies for diagnostic purposes. The demand from this segment too is expected to remain constant
120 100 80 60 40 20 0 2006 2007 13.17 2008 19.95 2009 26.91 2010 36.03 2011 48.23 2012 65.01 2013 87.64 2014 116.35 2015 154.46 Source: Frost & Sullivan
May 2010
Pre-Clinical Services
8.32
Confidential
15
KIPDC
Industry Size: The market revenue for 2009 was approximately 27 million USD. The revenues are expected to rise to USD 154 million by 2015. Phase of maturity: Market is in the Growth Stage Preclinical toxicology services have a CAGR of 34% through the forecasted period. India Advantage: Skilled manpower, low costs. Areas of Improvement: India still lags behind China in offering toxicological services. This mainly due to regulatory hurdles that limit the experimentation in higher mammals. Experimentation in primates is still an area that is seeing a lot of debate in India. Although the government has planned primate testing facilities on a Public Private Partnership basis, more needs to be done to facilitate experimentation in primates.
May 2010
Confidential
16
KIPDC
Animal Houses are typically understood to be enclosures where animals are raised and/ or bred for the purpose of lab testing while ensuring animal comfort. Animal houses can be large enclosures housing large animals like buffaloes, cows, horses, to smaller establishments containing small mammals like mice, rats, guinea pigs, etc. There is no particular classification of animal house types, but they can be classified either on the basis of the type of animals or on the basis of function of the animal house. One the basis of the type of animals sheltered in the facility, animal houses can be classified into Large Animal Houses and Small Animal Houses. There may be some containing both small and large animals, with common lab areas and separate animal housing areas.
Fig 8: Types of Animal Houses
Animal Houses
Animal area enclosed in cages Random Monitoring Testing facility Breeding enclosures
Animal area enclosed in wirehash Free Run Area surrounded by proper fencing Open Shed for animal resting Breeding Enclosures Testing facility
May 2010
Confidential
17
As seen in Figure 7 above, animal houses for small animals which house rodents like rats, mice, hamsters, rabbits etc., have indoor animal shelters. Such animal houses usually cater to studies performed for pre-clinical to clinical drug development. Animal Houses for large animals need to have shelters suitable for the larger animals. These areas may be open air (dogs) or caged (monkey). Apart from this, they also need to have a free run area for the natural frolicking activities of the animals as well as a shed area for resting of animals.
Type of Studies
Animal housed can be used for different types of studies depending upon the permission granted to the animal house. Small animals are used for pre-clinical drug testing, study of diseases like cancer as well as toxicology studies. Large animals in India are usually kept for Commercial purposes like sera production (eg. Horses and sheep) Antibody evaluation and production/identifying target molecules on big animals those can produce sufficient amount of antibodies when infected Nutritional studies General anti-venom studies Toxicology studies
On an average, nearly 300 horses are needed for studies related to antibodies production and sera-based studies in large animals Also, in a typical facility housing mainly small animals or rodents, nearly 50:50 ratio is maintained between animals used in studies and animals used for breeding, where the bred rodents are used for internal consumption.
KIPDC
The different types of studies performed in animal houses are mentioned in details below:
I. Preclinical Services
A] Pharmacokinetics (PK)
Single Dose PK Dose proportionality studies Absolute Bioavailability Multiple Dose Pharmacokinetics Multiple routes of administration: Intravenous, oral, subcutaneous, intraperitoneal and dermal. Tissue distribution intramuscular,
B] Efficiency Studies
Acute efficacy screening models Chronic efficacy screening models Based on the project suitable animal models will be used for screening Development of new animal models Genetically modified animal models
C] Toxicology
Abnormal toxicity Abnormal Toxicity is a European Pharmacopoeia standard for assessment of biological products. The test material is administered to mice and guinea pigs, which are then evaluated for signs of toxicity.
2010
Confidential
19
KIPDC
Animals used: mice and guinea pigs Specific toxicity Pyrogen testing A pyrogen is a substance (often bacterial) that causes elevation to an animals body temperature. Pyrogenicity testing seeks to find any possible fever-causing contaminants in items such as vaccines and injectable drugs. The rabbit pyrogen test, in use since the 1940s, requires the injection of the material into the rabbits blood stream and then monitoring for temperature increases. The rabbits sensitivity to the test is greatly affected by the strain of the pyrogen, as well as differences in age and gender Animal used: Rabbits Safety and potency tests Biological assays Bioassays are typically conducted to measure the effects of some substance on a living organism and are essential in the development of new drugs, and in monitoring environmental pollutants. For example bioassay test for pituitary , serum , glycogen etc. Animal used: Rabbits, toads Potency assays Potency assays are animal studies in which a defined animal model demonstrates a measurable, physiological change in response to application of the drug. Animal used: Hamsters, Guinea pigs Eye irritation test Ocular toxicity is determined by applying a test substance for one second to the eyes of 6 test animals, usually rabbits. The eyes are then carefully examined for 72-hours, using a magnifying instrument to detect minor effects. The ocular reaction may occur on the cornea, conjunctiva, or iris. It may be simple irritation that is reversible and quickly disappears or the irritation may be severe and produce corrosion, an irreversible condition. The eye irritation test is commonly known as the "Draize Test."
2010
Confidential
20
KIPDC
Animal used: Rabbits Systemic toxicity studies Male fertility studies These studies are conducted to determine the adverse effect of any drug on the male fertility. Semen parameters or reproductive organ histopathology and functioning are observed. Animal used: Rats, Dogs Female reproduction & Development toxicity studies The reproductive toxicity testing is intended to determine the effect of substances on gonadal function, conception birth and the growth and development of offspring. The oral route is preferred. Animal used: young adult rats Development toxicity is used to detect the potential of substance to produce embryo toxicity and birth defects. Animals used: Rats, Mouse, hamster and rabbits (young adult females) Female fertility study (Segment I) Teratogenicities study (Segment II) Teratogenicties studies are conducted to investigate the incidence of birth defects in the offspring when it is exposed to medicinal drugs. Animals used: Rat Perinatal study (Segment III) Animal used: Fetal and neonatal nonhuman primate, pregnant sheep, lamb, puppy, piglet and immature rodents
2010
Confidential
21
KIPDC
Local toxicity studies Dermal toxicity study- Dermal toxicity tests determine the potential for an agent to cause irritation and inflammation of the skin. This may be the result of direct damage to the skin cells by a substance. It may also be an indirect response due to sensitization from prior exposure. There are two dermal toxicity tests: i) Primary Dermal irritation Determines direct
toxicity. ii) Dermal Sensitization Assays for immune hypersensitivity of skin. Animal Used Albino rabbits Vaginal toxicity study Animal used: Rats, rabbits and dogs Rectal tolerance test The method determined the tolerance of a site( rectum) which comes into contact the medicinal product as a result of method of administration. Observation of the anal region and anal sphincter, clinical signs and faces is carried out. Animal used: Rabbits & Dogs Ocular toxicity studies Ocular toxicity is determined by applying a test substance for one second to the eyes of 6 test animals, usually rabbits. The eyes are then carefully examined for 72-hours, using a magnifying instrument to detect minor effects. The ocular reaction may occur on the cornea, conjunctiva, or iris. It may be simple irritation that is reversible and quickly disappears or the irritation may be severe and produce corrosion, an irreversible condition. The eye irritation test is commonly known as the "Draize Test." Animal used: Rabbits Inhalation toxicity studies Several groups of experimental animals are exposed for a defined period to the test substance in graduated concentrations, one concentration being used per group. Where vehicles used to help generate an appropriate concentration of the substance in the
2010
Confidential
22
KIPDC
atmosphere a vehicle control group should be used. Subsequently, observations of effects and deaths are made. Animals which die during the test are necropsied, and at the conclusion of the test surviving animals are sacrificed and necropsied as necessary. Acute inhalation toxicity is the total of adverse effects caused by a substance following a single uninterrupted exposure by inhalation over a short period of time (24 hours or less) to a substance capable of being inhaled. Animal used: Rats Allergenicity/ Hypersensitivity Guinea pig maximization test - The Guinea Pig Maximization Test is a widely-used test in the screening of contact allergens for the possibility that they may act as sensitizers in humans. Animal used: Guinea Pigs Genotoxicity a. AMES - This test uses amino acid requiring bacteria of at least five strains of Salmonella typhimurium and Escherichia coli to detect point mutations. Bacterial cells are plated on agar lacking an amino acid required by the test strain, and then exposed to the test compound in the presence and in the absence of an exogenous metabolic activation system. The principle of this test is that it detects new mutations which revert mutations already present in the test strains, and restore the functional capability of the bacteria to synthesize an essential amino acid. The revertant bacteria are detected by their ability to grow in the absence of the amino acid required by the parent test strain. Lack of bacterial growth may indicate that test compound is non-mutagenic. b. Micronucleus - This is a genotoxicity test system used for the detection of micronuclei in the cytoplasm of interphase cells to investigate the mutagenic potential of a test compound in vitro.
2010
Confidential
23
KIPDC
2010
Confidential
24
KIPDC
The number of Animal Houses in India is estimated to be close to 1300. Of these, 70% are under Medical Colleges and Research Institutes such as All India Institute of Medical Sciences (AIIMS) New Delhi, Christian Medical College (CMC) Vellore, Indian Institute of Science Bangalore National Center for Biological Sciences Bangalore, Center for Cellular and Molecular Biology Hyderabad, National Institute of Immunology New Delhi. 20% of animal houses are present in the facilities of pharmaceutical Companies such as Cadila Pharma, Dr. Reddys Labs, Ranbaxy Laboratories, Biocon, as well as International companies like MSD, Novartis etc. 10% animal houses are with Contract Research Organisations such as Advinus Therapeutics, Syngene, Jai Research Foundation, Raj Biotech, Intox Labs etc. A few animal houses are also well known for their bred strains which they supply to other animal houses. These stand alone animal houses include institutes like NTC, IISc, etc.
2010
Confidential
25
KIPDC
Thus, the volume of study performed by an animal house are difficult to estimate. However, it has been observed that on an average, the leading animal houses in India starts around 30 new studies on a yearly basis. The value of each study similarly depends upon a number of factors, ranging from cost of animals used for the study, to the complexity of the model used for the study. However, for a vanilla toxicology study performed for a group of 15 rats, the study can cost as much as INR 3 lacs.
2010
Confidential
26
KIPDC
27
KIPDC
7. 8. 9.
Each of the above mentioned infrastructural requirements are explained below in details.
Animal Rooms:
Animal rooms are where the animals are kept. This may comprise of either caging facility or housing system depending upon the type of animal that is kept. For smaller animals like rats, mice, rabbits, etc, cages are maintained, while for large animals like Horses, goats, cattle, etc. are kept in sheds and outdoor facilities with a proper fencing done. The animal housing system taken overall, should be designed carefully to facilitate animal well being, meet research requirements, and minimize experimental variables. The housing system should: Provide space that is adequate, permit freedom of movement and normal postural adjustments, and have a resting place appropriate to the species; Provide a comfortable environment Provide an escape proof enclosure that confines animal safety Provide easy access to food and water Provide adequate ventilation Meet the biological needs of the animals, e.g., maintenance of body temperature, urination, defecation, and reproduction Keep the animals dry and clean, consistent with species requirements Facilitate research while maintaining good health of the animals
2010
Confidential
28
KIPDC
To simplify servicing and sanitation, cages should have smooth, impervious surfaces that neither attract nor retain dirt and a minimum number of ledges, angles, and corners in which dirt or water can accumulate
Feeding and watering devices should be easily accessible for filling, changing, cleaning and servicing
Particular attention must be given to eliminate sharp edges and broken wires, keeping cage floors in good condition
<10
Up to 15
Up to 25
>25
17
14
Table explanation: eg., with a floor area of 96.7cm2, mice with cumulative weight more than 25gm can be kept. However, such mice should not exceed 3 in number for a small cage, and 7 in number for a large cage.
29
KIPDC
Humidity and temperature control in case the animal is caged, for example, in case of monkeys Fenced grounds/areas so that the animal can not escape from the surrounding, as well as some outside animal should not enter into the reserved area, eg. In the case of cows and horses
50 72 72 72 90
* A single monkey can weigh up to 25 kgs, hence cage floor area is determined by weight
2010
Confidential
30
KIPDC
Service area:
This area is reserved for the cleaning of animals and animal cages, as well as is concerned for all the routine sanitation activities. Sanitation is essential in an animal facility. Animal rooms, corridors, storage spaces, and other areas should be cleaned with appropriate detergents and disinfectants as often as necessary to keep them free of dirt, debris, and harmful contamination. Cleaning utensils, such as mops, pails, and brooms, should not be transported between animal rooms. These activities need to be done in service areas.
Animal Runs:
Large animals like horses, goats, etc. should have proper and spacious open-air animal runs (open areas) with a proper fencing and wired mesh, where these animals can be let open, play and run. This will help in keeping the physical and mental health of the animal in a stable condition. The animal runs may be separate for separate group of animals. This type of provision should always be made for animals with specialized locomotor pattern to express these patterns, especially when the animals are held for long periods. For e.g. ropes, bars, and perches are appropriate for branching non-human primates. Cages are often used for short-term (up to 3 months) housing of dogs and may be necessary for postsurgical care, isolation of sick dogs, and metabolic studies. Pens, runs, or other out-of-cage space provide more opportunity for exercise, and their use is encouraged when holding dogs for long periods.
Storage area
This area is used for maintaining the feed storage as well as spare cage storage and also for other necessary machineries or equipments related to animal house. Animals should be fed palatable, non-contaminated and nutritionally adequate food daily unless the experimental protocol requires otherwise. Feeders should allow easy access to food, while avoiding contamination by urine and feces. Food should be available in amounts sufficient to 2010 Confidential
31
KIPDC
ensure normal growth in immature animals and maintenance of normal body weight, reproduction, and lactation in adults. The animal feed should contain moisture, crude fiber, crude protein, essential vitamins, minerals crude fat and carbohydrate for providing appropriate nutrition.
Health labs
Animals need to be monitored for their health on a routine basis to ensure healthy animals available for studies to be conducted. Health labs enable checking of the vital statistics of animals and ensuring that the population is disease free and healthy. All animals should be observed for signs of illness, injury, or abnormal behavior by animal house staff. As a rule, this should occur daily, but more-frequent observations might be warranted, such as during postoperative recovery or when animals are ill or have a physical deficit. It is imperative that appropriate methods be in place for disease surveillance and diagnosis. Unexpected deaths and signs of illness, distress, or other deviations from normal health condition in animals should be reported promptly to ensure appropriate and timely delivery of veterinary medical care. Animals that show signs of a contagious disease should be isolated from healthy animals in the colony. If an entire room of animals is known or believed to be exposed to an infectious agent (e.g. Mycobacterium tuberculosis in non-human primates), the group should be kept intact and isolated during the process of diagnosis, treatment, and control. Diagnostic clinical laboratory may be made available. Health lab may be a part of the animal house, or located in another facility near the animal house, so as to ensure speedy checks if required. A typical health lab should include: - Blood pressure monitoring - Blood testing facilities - Stool testing - Ecto-parasite testing - Height/ weight monitoring - X-ray Facility - Diagnostic analytical tools 2010 Confidential
32
KIPDC
- Microbiology section - Pathology section clinical and surgical (optional) - And other routine health check facilities
Personnel Area
This area is meant for the staff and is used by them for their work. This also includes the administration section of the building. It is essential that the animal care staff maintain a high standard of personal cleanliness. Facilities and supplies for meeting this obligation should be provided e.g. showers, change of uniforms, footwear etc. Clothing suitable for use in the animal facility should be supplied and laundered by the institution. A commercial laundering service is acceptable in many situations; however, institutional facilities should be used to decontaminate clothing exposed to potentially hazardous microbial agents or toxic substances. In some circumstances, it is acceptable to use disposable gear such as gloves, masks, head covers, coats, coveralls and shoe covers. Personal should change clothing as often as is necessary to maintain personal hygiene. Outer garments worn in the animal rooms should not be worn outside the animal facility. Washing and showering facilities appropriate to the program should be available.
Incineration Facilities
Sacrificed animals should be properly disposed and immediately removed from the facility so as to reduce the chances of contaminations or any kind of infections. Incineration facilities may be part of the facility or may be conducted at a separate incinerator facility. Guidelines for incineration facilities are independent of those for animal houses. In case of large animals, burial may also be conducted for sacrificed animals. Local municipal corporations are also helpful in arrangement of disposal of sacrificed animals. Small animals are wrapped in specific bags designed for the purpose and immediately transferred to the cold 2010 Confidential
33
KIPDC
storage rooms wherein they are kept at -20oC temperatures until the time they are sent for incineration to the corporations involved in such kind of activities. (See Case Study for Mumbai)
2010
Confidential
34
KIPDC
Stored to -20oC
Bombay Municipal Corporation has incineration facility where they are either buried or burnt
Biomedical waste management unit maintained by Bombay Municipal Corporation have biomedical waste collection Vehicles. Similar facilities in Mumbai are maintained by Taluja group. Also there is SMS Enviroclean group who look after these issues
2010
Confidential
35
KIPDC
Regulatory Compliance
Every animal house supplying animals of any kind to the companies for test/ research purpose must be setup and supervised in accordance to Committee for the Purpose of Control and Supervision of Experiment on Animals (CPCSEA) which is duty bound to take all such measures as may be necessary to ensure that animals are not subjected to unnecessary pain or suffering before, during or after the experiments on them. CPCSEA guidelines are in accordance with Prevention of Cruelty to Animals Act (PCA). For this, government has made Breeding and Experimentation on Animals (Control and Supervision rules), 1988 which was amended thereafter in 2001 and in 2006, to regulate the experimentation on animals. Every such animal house or any institution having animal house with animals being sourced for research purposes should have an Institutional Animal Ethics Committee (IAEC) so that to maintain the quality and consistent ethical review mechanism. For experiments and studies involving some bacterial infections or fungal studies and other concerns similar to that like toxicology studies, there needs to be an Institutional Bio Safety Committee (IBSC) to regulate and supervise the experimentation and disposal of waste matter and animal dead bodies All the animal house are supposed to function in all respects in accordance with CPCSEA guidelines and routine inspection and survey needs to be get done by the owner to renew his certification. Other certifications which a particular animal house can go for but which are not mandatory are: DSTGLP (Department of Science and Technology Good Lab Practices) NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation for labs There are a few international accreditations: Accreditations from Jackson Laboratory, Maine, USA AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) accreditation. AAALAC International is a private, nonprofit organization that 2010 Confidential
36
KIPDC
promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. This is the only major organization that is only for animals FELASA (Federation of Laboratory Animal Science Associations) accreditation. The Federation of European Laboratory Animal Science Associations (FELASA) is composed, at present, of 12 independent European national and regional laboratory animal science associations. It can speak for laboratory animal scientists and technologists in at least 20 countries: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, the Netherlands, Norway, Spain, Sweden, Switzerland and the United Kingdom
However, very few Animal houses in India are having these international Accreditations like AAALAC and FELASA. The reason being: Non-competitive attitude of the animal houses in India to struggle and look forward for improving their facility standards Lack of proper planning and vision Lower revenues which restrict them from getting their facility maintained and functional according to the standards Improper business models which are not renewed routinely Dependency on repeat clients Lack of proper trained professional in India
2010
Confidential
37
KIPDC
Type of facility Animal rooms Service area Animal Run Storage Area Health Labs Personnel Area Autopsy/Test room
Incineration Facility
2010
Confidential
38
KIPDC
Registration of breeding
Inform authorities / CPCSEA about the details of every project; IAEC approval
2010
Confidential
39
KIPDC
All animal houses should function in accordance with Committee for the Purpose of Control and Supervision on Experiments on Animals (CPCSEA)
Facilities must be accredited with NABL (National Accreditation Board for Testing and Calibration Laboratories) and DSTGLP (Department of Science and Technology Good Lab Practices) to assure quality maintenance and safety of animals used in laboratory studies
All animals must be acquired lawfully as per the CPCSEA guidelines A health surveillance program for screening incoming animals should be carried out to assess animal quality
Animal care programs require technical and husbandry support. Institutions should employ people trained in laboratory animal science or provide for both formal and on-thejob training to ensure effective implementation of the program
For animal experiments involving bio-hazardous agents, the use of animals in such experiments require special attentions. The procedures and the facilities to be used must be reviewed by both the Institutional Bio-safety committee and Institutional Animal Ethics Committee (IBSC)
Transgenic animals are those animals, into whose germ line foreign gene(s) have been engineered, whereas knockout animals are those whose specific gene(s) have been disrupted leading to loss of function. These animals can be bred to establish transgenic animal strains. Transgenic animals are used to study the biological functions of specific genes, to develop animal models for diseases of humans or animals, to produce therapeutic products, vaccines and for biological screening, etc. These can be either developed in the laboratory or produced for R&D purpose from registered scientific/academic institutions or commercial firms, and generally from abroad with approval from appropriate authorities
Apart from DST/GLP and NABL accreditations, animal houses can also get international accreditations. These can help them while performing studies for international organizations, or for study results to be submitted to international drug authorities. While breeding imported strains of animals, the animal house may also be accredited by the international company from where the imports are done, to ensure quality of animals. Some of the well known accreditations are:
2010
Confidential
40
KIPDC
Accreditations from Jackson Laboratory, Maine, USA AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) accreditation. AAALAC International is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. This is the only major organization that is only for animals
FELASA (Federation of Laboratory Animal Science Associations) accreditation. The Federation of European Laboratory Animal Science Associations (FELASA) is composed, at present, of 12 independent European national and regional laboratory animal science associations. It can speak for laboratory animal scientists and technologists in at least 20 countries: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, the Netherlands, Norway, Spain, Sweden, Switzerland and the United Kingdom.
2010
Confidential
41
KIPDC
Most of the Pharma companies as well as CROs consider using their own Animal house facility animals for conducting tests and studies. However if the requirement is large, then they may opt for buying animals from outside. However, the animals are generally bought from the vendors who have good quality animals and have supplied to the sponsor earlier also. Following are the key points which are mentioned as gaps by the sponsors for any general Animal house facility functioning independently: Lack of proper accreditations at national level, which include bare minimum like ISO or DST accreditations. The study results, if needed to publish at an international level, need to have animals that are from a certified facility following GLP, which gives an extra edge towards the acceptance of the results Sometimes necessary Animal certificates are also needed like Certificate of Birth or Genetic Monitoring Certificate for a particular stock, which may not be available in proper form with an animal house Animal health is again a major concern. Animal may be supplied to the sponsor in a poor health condition, or may be a significant percentage of animals in a stock may not be at a good physical level top conduct experiments or studies. Maintenance of typical animal models like Diabetes mouse or Cancer models all the time is again not possible for all kinds of animal houses, since extra care has to be taken for these models Breed mixing and maintenance is again an issue which is encountered some of the times. Like, there is a possibility of strain mixing in the animal house which may then contaminate the stock and the same is unknowingly transferred to the sponsor. This may again foul the results of the experiment Supply of animals is also a problem to some extent because if a large sample is required for some test, the animal houses ask for a time of atleast one to two month so as to raise the animals. That is, they act only on getting the orders from sponsors and very few animal houses in India have necessary stock ready all the time
2010
Confidential
42
KIPDC
2010
Confidential
43
KIPDC
Advanced Scientific Research (JNCASR). National Institute of Mental Health and Neuro Sciences is Indias leading Neurology research center. o Karnataka is home to the second largest number of Medical Colleges in India at close to 40.
2010
Confidential
44
KIPDC
2010
Confidential
45
KIPDC
2010
Confidential
46
KIPDC
Government Support Bangalore Biocluster Karnataka was first in the country to announce Biotech Policy in the year 2001. This policy was revised in 2009 with a number of additional benefits. Single Window Clearance agency has been created to fast track project clearance. Projects with value over USD 10 Million to receive special package. All research labs to come under the Green category. State-of-the-Art Animal Quarantine and BioSecurity Facility to be set up at Bangalore International Airport Bangalore is considered Indias main Biotech Hub. The Competitive Strengths of Bangalore are suited for supporting Biotech Cluster. This Biocluster is also ably supported by allied industries such as the Large IT sector and BPO sector. Due to the relatively high R&D and capital demands of the Life Sciences sector Karnatakas relative strength in R&D, Proactive government policies, world class Institutes and Active Public Private Partnership makes Bangalore and natural Hub for Life Sciences research in India.
Stake holder groups The Bangalore Cluster is unique in having Institutions for Collaboration (IFCs), which focus on cluster communication and collaboration. Examples include the Association of Biotechnology Led Enterprises (ABLE), the Vision Group on Biotechnology, which has organized the nations flagship annual biotechnology exhibition, Bangalore-Bio International Fair (Bangalore-Bio), since 2001. Bio-Venture Fund of US$
Research Institutes
Karnataka is home to many world class universities such as IISc, NCBS, JNCASR, NIMHANS. 15 out of the 30 universities offering degrees in biotech in India are based in Bangalore. Karnataka has the second highest number of medical colleges in India at close to 40. Proposed National Center of Excellence in Stem Cell Research is expected to come up in Bangalore
Source: Frost & Sullivan
2010
Confidential
47
KIPDC
Strengths Strong Scientific resource base with presence of a large number of of Research Scientific Institutes focused on Life Science Research Large Second Concentration Largest of of Oriented Life Science Companies number of Medical manpower Veterinary due to College in India Availability presence Institute Acknowledged R&D capital of India Proactive Government Policies Weakness Infrastructure Bottlenecks Lack of quality manpower due to lack of specific courses which Research -
Opportunity Large Market Demand for Lab Animals and Services (Initial estimate of
50,000 animals annually) Minimal Competition- There is just one major independent lab animal provider in Bangalore. Increased Drug Discovery Outsourcing activity with emphasis on Biology
Excellence in Stem Cell Research will boost demand. Threats Highly regulated environment for Animal Experimentation Competition from Hyderabad Requirement facility can for High increase standard initial
2010
Confidential
48
KIPDC
Special Economic Zone (hereinafter referred as as SEZ) is a geographical region that has economic laws that are more liberal than a country's typical economic laws. An SEZ is a trade capacity development tool, with the goal to promote rapid economic growth by using tax and business incentives to attract foreign investment and technology. Today, there are approximately 3,000 SEZs operating in 120 countries, which account for over US$ 600 billion in exports and about 50 million jobs. By offering privileged terms, SEZs attract investment and foreign exchange, spur employment and boost the development of improved technologies and infrastructure. There are 13 functional SEZs and about 61 SEZs, which have been approved and are under the process of establishment in India. As observed in various interactions with stakeholders of animal houses, an SEZ for an animal house may not be of immediate value to the system. Advantages of having an Animal House located in an SEZ: Availability of an animal house in a Pharma/ biotech SEZ will be of immense value to the Pharma/ biotech companies who will not need to have to maintain their own animal houses or outsource to animal houses far from their location, thereby making monitoring activities simpler The animal house will be assured of a captive client base from the companies in the vicinity Presence of other animal houses in the same SEZ can facilitate sharing of resources like health labs and incineration facilities. This can help in reduce the running cost of the facility Being inside an SEZ can help the animal house in the cost of sourcing international strains of animals. However, this has to be explored in further details.
2010
Confidential
49
KIPDC
The advantages listed above for presence in an SEZ however, are not unique. While companies within the SEZ may choose to conduct their studies in an animal house in the same SEZ, they will also consider other factors such as capability of the animal house and pricing of study before awarding a project to an animal house. If presence in an SEZ constraints the animal house with respect to availability to other companies outside the SEZ or other similar constraints with respect to facilities, the animal house may not benefit from being present in the SEZ.
(A) The Units set up in an SEZ which have begun to manufacture / provide services during the financial year beginning April 1, 2005 will get the following exemptions: 100% exemption of profits and gains from business for the first 5 years.
50% exemption on profits and gains from business for the next 5 years.
50% exemption to the extent that such amounts is re-invested in the SEZ Special Reserve Account.
If the SEZ Unit has already availed of benefits for 10 years under Section 10A of the ITA, the above exemptions are not available. Further, when a Free Trade Zone (FTZ) or an Export Processing Zone (EPZ) is converted into an SEZ, the Units, which have already availed of the 10-year tax exemption in an FTZ or EPZ, cannot avail of the Section 10AA exemptions.
(B) Losses falling under the heads Profits and Gains from Business or Profession and Income from Capital Gains can be carried forward / set off as long as such loss is related to the business of the SEZ Unit.
(C) Capital Gains on transfer of assets in case of shifting of an industrial undertaking from an urban area to an SEZ shall be exempt, provided that 1 year before, or 3 years after the transfer
2010
Confidential
50
KIPDC
(i) machinery / plant was purchased for the business of the industrial undertaking in the SEZ, (ii) building or land was acquired or building was constructed in the SEZ, (iii) the original asset was shifted and the establishment was transferred to the SEZ and (iv) the assessee incurred such other expenses as are notified by the Central Government
(D) Interest income received by a non-resident or a person who is not ordinarily resident in India, on a deposit made in an OBU situated in an SEZ, shall be exempt from total income
(E) No tax deduction shall be made by the OBU from interest paid: (i) On deposits made on or after April 1, 2005 by a non-resident or a person not ordinarily resident in India; or (ii) On borrowings on or after April 1, 2005 from a non-resident or a person not ordinarily resident in India
(F) The gross total income of an assessee having an OBU or an assessee being a Unit of an IFSC shall be deductible to the extent of 100% for 5 consecutive years from the year of grant of permission under the Banking Regulation Act / SEBI / other relevant law and 50% for the next 5 years12. It further defines the exempted income, which is:
Income from business referred to in the Banking Regulation Act, 1949, or any other Unit which develops, develops and operates, or develops, operates and maintains an SEZ ;
2010
Confidential
51
KIPDC
(G) Exemption from Securities Transaction Tax available to taxable securities transaction entered into by a non-resident through the IFSC.
Other Benefits
Exemption from Customs Duty: SEZ Units may import or procure from the domestic sources, duty free, all their requirements of capital goods, raw materials, consumables, spares, packing materials, office equipment, DG sets etc. for implementation of their projects in the SEZ without requiring any license or specific approval Goods imported/procured locally which are duty-free could or should be utilized within the approval period of 5 years Domestic sales by SEZ Units will be exempt from Special Additional Duty Domestic sale of finished products, by-products is permitted on payment of applicable Customs duty Domestic sale of rejects, waste and scrap is permitted on payment of applicable customs duty on the transaction value Exemption from applicable excise duty on goods brought in from the DTA to an SEZ
100% FDI under the automatic route is allowed in the manufacturing sector in SEZ Units, except for arms and ammunition, explosives, atomic substances, narcotics and hazardous chemicals, distillation and brewing of alcoholic drinks and cigarettes, cigars and manufactured tobacco substitutes
2010
Confidential
52
KIPDC
Exemption from the applicability of Press Note 2 (2005) that prescribes certain conditions that a foreign investor proposing to make foreign direct investment in real estate sector in India has to satisfy.
Service Tax
Exemption from Service Tax to the Developer and the SEZ Units to carry on authorized operations in the SEZ. Service tax exemption granted only to Units in the DTA providing services to a Developer or to a Unit.
2010
Confidential
53
KIPDC
Labour laws
All labour laws as applicable within the country apply in an SEZ.
Stamp duty
No stamp duty is chargeable in respect of any instrument executed, by, or, on behalf of, or, in favor of, the Developer, or Unit or in connection with the carrying out of the purposes of the SEZ
Sub-Contracting
SEZ Units may sub-contract part of their production or production process through Units in the DTA or through other EOU / SEZ Units SEZ Units may also sub-contract work from the DTA exporters, and export from the SEZ Units can be set up to provide manufacturing services to overseas entities subject to certain conditions
Income-tax benefit as applicable to physical export under Section 80 HHC of the Income Tax Act
2010
Confidential
54
KIPDC
Benefits of SEZ Setting up in an SEZ offers the a lot of tax benefits and incentives as highlighted. Customs exemption import of equipment and sale in the domestic market. By setting up in a Pharma SEZ an assured clientele is accessed Single Window clearance mechanism are in place in most SEZs and some of them have Pre approved Pollution Control Clearance. Common utilities such as Electricity, Water Supply and Incinerator services. Good connectivity and infrastructure.
Analysis
Limitations of SEZ 95% SEZs are focussed toward manufacturing set ups which have very little of no requirements for Animal House. Most Pharma/Biotech SEZs are developed by single partys e.g. Serum Institute SEZ in Pune, Biocon SEZ Bangalore etc. These companys possess their in house Animal House facilities and also do not source from local vendors. No access to common equipment facilities as most of the companies are manufacturing facilities and not R&D facilities
Strategic Recommendations We feel that the benefits of setting up in an SEZ are not that significant. Instead focus on setting up in a Biotech Park which may not offer as much benefits as an SEZ but will be able to sustain the business better. Biotech Parks are more focussed towards R&D and some companies house their R&D sets with them. Bioparks are also know to nurture small and medium companies that do not have the capital to set up a full fledged Animal House and Toxicology division and could provide a captive client base. Most Bioparks generally have common instrumentation facility and air conditioning and other utilities which can reduce the capital expenditure.
however, that is rare in practical scenario and difficult to implement. Frost & Sullivan surmises that the financial benefit of setting up an animal house in an SEZ is not significant.
2010
Confidential
55
KIPDC
Introduction: The Shapoorji Pallonji Biotech Park (SPBP) is spread over 300 acres near
Hyderabad, India and was the first of its kind in the country. It is the hub of Genome Valley, Indias first state of the art biotech cluster for life science research, training and manufacturing activities. This is one of the most successful Biotech Parks in the country working on a Public Private Partnership model between the Shapoorji Pallonji group and the Andhra Pradesh Government.
Facilities Overview:
The park offers common effluent treatment facilities, power back up, compressed air and other facilities. It also has a biotechnology incubation center to support start up companies in translating their research ideas into commercially viable technologies without making large R&D investments up front. Modular laboratory units with standard facilities and services Telecom network Power and water supply and sewerage treatment Common effluent treatment facility Security, housekeeping, roads, fire detection and protection and landscaping
Assistance in getting started Technology Incubation Centre Facilitates validation of science and technology without making large scale investment up front Pilot Plant Support in meeting statutory requirements
2010
Confidential
56
KIPDC
All the companies that are housed in this park are focused on R&D activities. 87% of the companies are focused on human health related applications. Out of these 57% are Biopharmaceutical companies such as Avesthagen, Biological E etc. 22% are Contract Research Organizations such as Vimta Labs, Albany Molecular Research Inc. etc. 9% are Pharma companies who have housed their R&D set in this park, companies such as Uni Sankyo, Sandor etc. This 87% of companies provide a potential captive customer base for an animal house as majority of the companies have housed their discovery, development or pre clinical activities in this park.
Business Potential:
A typical Biopharmaceutical R&D facility consumes roughly 500 rats/month, 500mice/month and 30-50 Guinea Pigs and Hamsters. The price of the animals can vary from INR 200 for ordinary animals to INR 4000-10000 for highly specialized animal. This is dependant on the kind of R&D programs of the companies. Some small and medium companies might have molecules is an advanced stage of development where in they would require mammalian studies such as dog and 2010 Confidential
57
KIPDC
primate toxicology. Primate toxicology studies are yet to take off in a big way in India and majority of the companies are forced to look at companies in China mainly due to stringent regulatory restrictions in India. Dog toxicology studies too are in a nascent stage but are slowly picking up. Indian companies can charge a premium and margins in this business can vary from 50-75% In order to understand fully the potential of setting up an Animal House facility in a Biotech Park a detailed analysis on the tenants and their R&D program is required.
2010
Confidential
58
KIPDC
completed over 200 studies for more than 60 satisfied customers. The animal facility is distributed in an area of nearly 4200 sq ft.(500 sq meters). supported with qualified skilled animal care staff The facility meets the requirements as per the guidelines of Committee for the Purpose of Control CPCSEA. (Registration 449/01/bc/CPCSEA) An Institutional Animal Ethics Committee number is & Supervision of Experiments on Animals (CPCSEA) and is registered with the and is and Preclinical Pharmacology (Efficacy studies / Acute & Chronic Models) Pre-clinical safety Pharmacology Pharmacokinetic Studies In vivo Toxicology In vitro Toxicology (Microarray based predictive toxicology) Biological Testing Animal studies Custom-made Polyclonal Antibody Services Tissue Culture based veterinarians
Services
(IAEC) has been constituted as per CPCSEA guidelines and reviews the scientific projects of the institute quarterly. The facility undertakes animal breeding, management, care and husbandry practices. The facility houses small laboratory animals viz. mice, rats, rabbits. The facility is engaged in the production of quality animals by undertaking various quality control programs and preventive measures.
2010
Confidential
59
KIPDC
Swiss albino BALB/c C57BL/6 NUDE mice B6D2f1 DBA2 C3Hej SCID mice
Rat
Guinea Pigs
Hartley
Figure15: Clientele
2010
Confidential
60
KIPDC
2010
Confidential
61
KIPDC
Pre-Orders are taken from clients 2-3 months in advance Prefer the orders which will continue for
more than 6 months
Actual sales: nearly 2000 mice per month. Monthly sales: nearly 15 to 20 lakhs per month YoY growth observed for animal sales: 10-12%
2010
Confidential
62
KIPDC
IAEC Institutional Animal Care and Use Ethics Committee is recognized by CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals, Govt. of India) for conducting any study involving lab animals and for sales of lab animals
Recognition by Department of Biotechnology for Institutional Biosafety Committee for conducting studies involving r-DNA
Under process
NABL (ISO 17025) main assessment due GLP implementation underway
Area requirements:
Facility has nearly 26 animal rooms. Each animal room is roughly 350 ft2 Total animal room area : 26*350ft2 = 9100 ft2 Central labs: Three. Each Cental lab is nearly 500 ft2 Total lab area: 3*500ft2 = 1500 ft2 In the facility, the labs are shared for animal studies as well as routine monitoring and other procedures. Labs are for multipurpose use.
2010
Confidential
63
KIPDC
Washing room (Cage washing and Autoclaving equipments) Personnel area (1 room) Temperature Control vehicles and facility for vehicle disinfection Fumigation facility
Future plans:
Adding four more animal rooms to the existing facility: Cost will be around 25 lakhs INR
Low
High
1 2 3 4 5
Untapped potential
2010
Confidential
64
KIPDC
2010
Confidential
65
KIPDC
Type of projects that can be sourced in India but are not there presently
Presently, the animal house preclinical trending is at a growing/Sprouting stage in India. With India, nowadays been seen as a preferred site for doing clinical trials studies which include preclinical and Phase I-IV studies, there resides a lot of potential in the usage of a broad spectrum of animal models for different types of studies.
Figure17: Clinical trials in India, 2008-2015 (e)
1200 1100 1000 900 800 700 600 500 400 300 200 100 0
1106
2008
2009
2010
2011
2012
2013
2014
2015
The number of clinical trials in India are expected to grow at a CAGR of about 18% till 2015. This increase will be fuelled by the fact that India is a preferred destination for companies due to low cost and large patient pool for broad spectrum of diseases. This is turn is going to fuel the usage of animal models for the preclinical testing and evaluation studies. The demand that is going to be there for animals will be pretty high in years to come, and that will increase the dependency of organizations on private animal house setups.
2010
Confidential
66
KIPDC
1200 1100 1000 900 Number of Trials 800 700 600 500 400 300 200 100 0 42 189 81 39 2008 223 84 59 2009 55
Clinical Trials by Phase in India 133 121 105 87 543 76 65 315 252 111 82 2011 146 102 2012 175 122 2013 201 221 393 472 597
89 61 2010
141 2014
155 2015
Phase I
Phase II
Phase III
Phrase IV
Its clearly visible that the number of phase-I activities are on wave in coming few years and hence the preclinical activities will take a giant leap. The more number of clinical trials again will need the CROs and the big Pharma companies to look into the available options for sourcing the animals from outside their facility depending upon the type of study being done and the quality of outcome that is expected by the sponsor
2010
Confidential
67
KIPDC
Opportunity Areas Projects in oncology and CNS areas are witnessing a growing trend and are presently occupying a significant proportion of revenues at an overall level in Clinical trials market.
62% of the Phase I revenue is generated from oncology trials in India, with only 3% contribution to Phase I from Diabetes due to the fact that most of the diabetes drugs are in phase II/III/IV Phase 2 revenues are dominated by CNS segment with 19% share, diabetes segment with 18% share, Immunology/Vaccines with 16% share , Bone disorders and pain management with 16% share followed by Cardiovascular segment with 15% share Diabetes remains as a predominant revenue contributor in Phase III with 23% revenue contribution followed by Cardiovascular with 17%
68
KIPDC
PART II Financial Viability Assessment comprising of CAPEX requirements and revenue estimation
2010
Confidential
69
KIPDC
The cost of an animal house is dependant upon a number of factors. The most important of them being the land/ area apportioned for the setup, followed closely by the type of facility planned. A facility which is planned for international approvals requires higher quality infrastructural requirements as compared to a GLP approvable facility. Since animal houses are service models, the accreditations of the facility also impact the clients which are serviced by the facility, as well as the pricing commanded by the organisation.
2010
Confidential
70
KIPDC
To keep an animal house of 5000 animals, the animal house needs to have sufficient rooms, with adequate service corridors, ventilation, as well as supply of fresh air, water and feed. It has been found from our study, that a typical animal house which can accommodate 5000+ animals, including breeding rooms as well as separate rooms for animals, needs an investment ranging from INR 1 crore to INR 10 crores. This cost includes the cost of the facility building, complying with the regulatory requirements, the air-conditioning, water flow mechanism, paintwork and specialized doors as per the animal house requirements. The facilities are typically 2 storied, with rooms distributed equally between the two floors.
2010
Confidential
71
KIPDC
Lab Area
Animal houses also contain a lab area within their premises. This area is usually considered within the total floor space required in an animal house. However, when the focus of the animal house shifts from only breeding and supplying of animals to also conducting toxicology and pharmacology studies, there is a definite infrastructural requirement for the labs. The cost of setting up a serviceable lab infrastructure within an animal house to conduct the basis tests can range from INR 10-25 lacks depending upon the size of lab and the types of animals kept in the facility. However, it the lab is meant for complex toxicology tests, which can be NABL certified, the facility cost can range from INR 50 lacks.
Equipments Requirement
A typical animal house has requirements of cages and service equipments for keeping the animals. These requirements also vary according to the certification of the animal house, as well
2010
Confidential
72
KIPDC
as number of animals kept in the same. However, the costs of such equipment is not very high and does not exceed INR 35-40 lacks for a 5,000 rodent facility. Typically an animal house also has a lab area where the animals are dozed, or tested upon. This area requires equipment certified internationally, which can conduct tests on various types of animals. A typical lab facility adjoint to an animal house will require an investment of INR 25-30 lacks.
2010
Confidential
73
KIPDC
2010
Confidential
74
KIPDC
Transportation costs are operational expenses incurred by the animal house for transport of animal supply or of the materials related to animal health and welfare. This cost remains upto 6% of the net revenue. Fixed Upkeep Costs These are the costs that can occur monthly or yearly, but remain constant on a year to year basis. These costs do not depend upon the number of animals of the facility, but rather the infrastructure of the facility. This includes the cost of air-conditioning, the water treatment, electricity, etc. This cost is again locational dependant since the electricity and water costs are dependant on the state infrastructure. However, for a typical animal house it varies between 2030% of the total operational costs. Cost of Acquiring Animals An animal house has to continually renew its breeding pair. This can be done either from its existing supply or externally from another animal house. Also, new strains of animals need to be typically acquired from other animal houses which develop those strains. Acquired animals are either sourced from within the country or from international reputed labs like Charles River Labs or Jackson Labs, etc. Acquisition of canines needs to be done on a periodic basis since canine breeding is not allowed in India. The cost of a beagle dog (the most common dog variety for studies) is usually INR 1 lac/ dog. The cost of small animals varies according to the strain of the animal. A BalbC white mice can be acquired from within India for as low as INR500 per pair, while the same can be acquired from Jackson Labs for INR 1500 per breeding pair. However, for a running animal house the initial investment on animal acquisition remains high, but reduces over the next years as it supplies its own breeding pairs. Other Variable Costs This includes heads like diagnostic testing, autoclaving expenses, and typical unprecedented expenses. For a small animal facility this is expected to range from INR 2lacks to higher, depending on the type of expense. Changes in the air filtration system, for e.g. can be upto INR 30 lacks.
2010
Confidential
75
KIPDC
This section uses an example of a GLP certified facility which houses 5,000 small animals (rodents). The facility is AAALAC approvable, or else has a AAALAC approval.
Example 1: AAALAC Approvable Animal House, with 5,000 small animals
2009 360 120.0 240.0 259 70.0 37.5 131 90.0 7.2 33.9 20.0 101 133.5 235 1,023
2010 420 132.0 288.0 253 70.0 41.3 140 94.5 7.9 37.3 2.0 167 133.5 301
2011 491 145.2 345.6 266 70.0 45.4 149 99.2 8.7 41.0 2.0 224 133.5 358
2011 574 159.7 414.7 281 70.0 49.9 159 104.2 9.6 45.1 2.0 294 133.5 427
Net Sales Animal Supply (Breeding business) Toxicology Tests Operational Cost Fixed Upkeep Costs Cost of acquiring animals Recurring Variable Costs Personnel Cost Transportation cost Material cost (feed, bedding, etc.) Other Variable Cost Profit (EBIT) Depreciation Operating Cash Flow (incl Tax) NPV#
2010
Confidential
76
KIPDC
Typically, such a facility will source its animals regularly from an international reputed lab and hence have a higher animal acquisition cost. Also, the personnel will have to be trained better, thereby ensuring adherence to the norms as required by AAALAC. As seen in the cash flow statement above, the facility has high revenue from toxicology studies than from sale of animals. This is because the animals are typically sourced from international labs and bred for a short period in the lab. A lab animal is typically bred for 5 generations to preserve its strain. Therefore, Pharma companies and CROs who source the animals for conducting tests prefer to source the animals from the international labs, and would approach a AAALAC approvable facility when in need of animals on a short notice. The animal house thus earns a revenue of INR1.2 cr from animal breeding and supplying business. However, the animal house has forward integrated and also performs toxicology tests for specified strains, as per client requirements. Since AAALAC approvable animal houses are few in number, and their facilities are at par with the facilities in Pharma companies; also since Pharma companies can use the results form these facilities for international submissions, they outsource some of their studies to such animal houses. This is a higher valued business with lesser competition, and though the animal house may perform lower number of studies, it will have a better topline from this business. In this case the animal house earns twice the revenue from toxicology studies than from animal supplies. The business for animal supplies is increasing on a 10% basis YoY, however, the toxicology studies business is increasing on a 20% yoy growth rate. This is mainly because of the increasing number of pre-clinical molecules, as well as increased trust of Pharma companies in the animal houses. The infrastructural investment made by the animal house for the facility are as follows:
One-Time Investments Infrastructure cost Building cost Animal House GLP Animal House non-GLP Lab facility GLP Lab facility non-GLP Equipment Cost Animal House equipment Lab equipment (for studies) 1,335 1,050 1,000.0 50.0 285 35.0 250.0
2010
Confidential
77
KIPDC
Excluding the land cost, which will be dependant upon the location of the facility, the one-time investment made on the infrastructure of the facility is INR 13 Cr. For this exercise we have considered a straight line depreciation for the infrastructural costs, at 10% depreciation. It is expected that with ageing of the facility as well as changes in the regulations, there will be a renovation/ change in facility at the end of 10 years. The net operating cash flow value for this animal house which is AAALAC approvable, over a period of 4 years is estimate to be INR 10.2 Cr.
This section uses an example of an animal house which houses 5,000 small animals (rodents). The facility is GLP approvable, or else has a GLP approval.
Example 2: GLP Approvable Animal House, with 5,000 small animals
2009 236 200.0 36.0 150 46.0 10.0 74 45.0 12.0 17.0 20.0 86 16.2 102 513
2010 261 220.0 41.4 124 46.0 5.0 71 47.3 13.2 10.6 2.0 137 16.2 154
2011 290 242.0 47.6 128 46.0 5.0 75 49.6 14.5 10.6 2.0 162 16.2 178
2011 321 266.2 54.8 132 46.0 5.0 79 52.1 16.0 10.6 2.0 189 16.2 205
Net Sales Animal Supply (Breeding business) Toxicology Tests Operational Cost Cost of Upkeep (recurring) Cost of acquiring animals Other Costs People cost Transportation cost Material cost (feed, bedding, etc.) Other Variable Cost Profit (EBIT) Depreciation Operating Cash Flow (incl Tax) NPV#
Typically, such a facility will source its animals regularly from an Indian lab like NIN (National Institute of Nutrition) which have their own strains, or do a one time purchase from an international reputed lab and use those strains for a longer period. Thus cost of animal 2010 Confidential
78
KIPDC
acquisition is comparatively lower here. Also, the personnel can have lower experience and thus can be sourced at a lower cost. As seen in the cash flow statement above, the facility has high revenue from sale of animals than from toxicology studies. This is because the animals are typically sourced from international labs and bred for a long period in the lab. While a lab animal is typically bred for 5 generations to preserve its strain, here the animals can be bred multiple times, and its strain tested every few generations. Thus, the animals are cheaper to source from such an animal house than from international labs. However, since the labs are not accredited, Pharma companies and CROs typically do not want to outsource their toxicology tests which they would like to submit with NCE papers to these labs. The animal house thus earns a revenue of INR 2 Cr from animal breeding and supplying business. However, the toxicology test business in this case is much lower, with revenue of INR 36 lacks only. This business is an adjacent revenue earner due to the sale of animals, where some clients may prefer the animal house to conduct the toxicology tests in some cases. The business for animal supplies is increasing on a 10% basis yoy, however, the toxicology studies business is increasing on a 15% yoy growth rate. This is mainly because of the increasing number of pre-clinical molecules, but a limited trust of Pharma companies. The infrastructural investment made by the animal house for the facility are as follows:
One-Time Investments Infrastructure cost Building cost Animal House GLP Animal House non-GLP Lab facility GLP Lab facility non-GLP Equipment Cost Animal House equipment 10lks Lab equipment (for studies)
Excluding the land cost, which will be dependant upon the location of the facility, the one-time investment made on the infrastructure of the facility is INR 1.6 Cr.
2010
Confidential
79
KIPDC
For this exercise we have considered straight line depreciation for the infrastructural costs, at 10% depreciation. It is expected that with ageing of the facility as well as changes in the regulations, there will be a renovation/ change in facility at the end of 10 years. The net operating cash flow value for this animal house which is GLP approvable, over a period of 4 years is estimate to be INR 5.13 Cr.
Conclusion
Though a GLP approvable animal requires lower investments, its revenue earning potential is limited. The profitability of a GLP approvable animal house may also be higher in the short term due to the lesser cost of animal acquisition and animal care, however, considering the values earned, an AAALAC approvable facility has a higher net present value.
2010
Confidential
80
KIPDC
PART III Land Requirement and Site Suitability Assessment for Setting up of an Animal House
2010
Confidential
81
KIPDC
Land Requirement Criteria Land for small animal facility Additional land for expansion of small animal facility Additional land for canine facility Gardening and surrounding land Total Land Requirement
Thus, for a facility which plans to expand in the future over the next 5 years, the land requirement is 1.65 acres (72,000 sq ft). The land required for an AAALAC approvable small animal facility is 35,000 sq ft. However, this can also be built over two levels than flat on the ground. We have still considered this area as a net land requirement since an animal house building will also need a surrounding area for various administration and regulatory purposes. The given land area also gives the facility the flexibility to plan the animal house as per the best suitable option during construction. Also, since this area includes the lab area for the facility, it gives the animal house to have a large lab area which can be state-of-art and also cater to canine requirements over the next few years. Though the animal house may initially have 5,000 small animals, the demand may increase over a period of years, as the market reputation of the facility increases and demand for studies increases, the facility may need to increase the number and strains of animals kept within. For the same purpose, an additional housing area may be needed, which can then be constructed adjacent to the existing facility. The land requirement for such a facility will be lower since this
2010
Confidential
82
KIPDC
new facility can share the common lab areas, storage, washing areas, etc. with the original premises. As demand and reputation of the animal house increases, and also as studies on large animals within India increase, the animal house may expand to have a small canine facility. The facility can initially house 40 canines. The minimum requirement for the same would be 2,000 sq ft. This is also low since this facility can share the common areas like storage and labs with the original animal house facility. To ensure compliance to pollution requirements as well as any plans for waste water management, it is suggested to keep a minimum gardening area of 20,000 sq ft. Thus, the minimum land requirement of an animal house which plans to grow and increase its service offerings over the next 5-10 years is estimated to be 1.65 acres. However, Frost & Sullivan recommends the total land area allocated for an animal house to be 2 acres. This additional land may initially be the gardening area, however, it can be utilized as per the demand and market dynamics. If the canine facility needs further expansion, or if the requirements of the storage and lab areas of the canine facility are not fulfilled by the main animal house due to high inflow of projects, the facility can then create additional labs and storage areas in the free land. If required, the animal house can also create its own power generation and waste management shed area in the free land.
2010
Confidential
83
KIPDC
2010
Confidential
84
KIPDC
d) Availability of raw materials the facility should be located close to a source to ensure availability of feed and bedding for the facility through the year e) Demand from companies an animal house cannot be profitable unless there is a demand for its services. The facility should be set up close to its clients, where their requirements can be met. This may be close to biotech or Pharma company clusters, or parks f)
Competition the animal house should not be in a location with very high competition
and other successful established animal houses in the vicinity. This can impact the business from future clients
Miscellaneous Factors
Apart from the above mentioned factors, some other factors also determine the selection of a site for an animal house. These are listed below: a) Regulatory requirements for site approvals the animal house should be able to satisfy the requirements of the regulatory authorities for setting up of an animal house b) Pollution norms the animal house should comply to the pollution norms, and the location should enable it to comply with the norms satisfactorily. This can include waste water management facility availability, waste matter management, etc. c) Animal Rights Compliance the facility should be located in an area which will ensure that the animals are comfortable d) Miscellaneous local reasons there can be many other miscellaneous factors which can impact the decision of setting up an animal house in a location
Each of the above mentioned parameters have been prioritized and rated by Frost & Sullivan as per their importance on a scale of 0-10. The most important factors have been rated 10.
2010
Confidential
85
KIPDC
Parameters
Rating 10 3 5 8 7 2
Cost-based Land cost Raw material cost Site certification Investments (for GLP/ NABL etc.) Labour Costs - Compensation of Vets, Animal Caretakers etc. Basic utilities (Electricity, water supply) cost Transportation cost Non-cost based Availability of land Availability of skilled professionals Availability of transportation Availability of Raw materials Demand to Biotech/Pharma companies/CROs Competition in nearby surroundings Others Regulatory Requirements for Site approvals, etc. Pollution norms Animal right activities Miscellaneous local reasons
10 5 2 3 8 7
10 5 8 3
As seen in figure above, among the cost based factors, Land cost is the most important factor while setting up of a facility. This is the highest investment. However, it is also a long term onetime investment. Labour cost is a recurring cost and is the next important factor, with a rating of 7/10. Amongst non-cost based factors, land still remains a factor, since availability of the desired land is crucial for setting up of a facility. Also important is the demand from biotech/ Pharma companies to ensure revenue flows into the company. Regulatory requirements are the most important feature when an Animal house starts business, since this determines the type of clients and the business potential from the animal house.
2010
Confidential
86
KIPDC
Land attractiveness for the project the land should be suitable for setting up of an animal
house and the location should also fulfill the key parameters as listed in the section above
On the basis of our interactions with various animal houses within India, Frost & Sullivan have rated each of these key features from 0-10, where 10 is the highest score for the most important factor.
Land Parameters Land Cost Availability of Land Stamp Duties etc Legal Requirements (before setting up Animal House on Land) Approval from neighbouring dwellers/ companies Land Attractiveness for the project
Rating
8 7 2 5 3 10
2010
Confidential
87
KIPDC
As can be seen in the figure, Land Cost remains an important factor; however, the suitability of the land for the project, on the basis of the predetermined parameters becomes the most important factor. Availability of land and the legal requirements to use that land for an animal house the next factors which need to be kept in mind while selecting land for an animal house.
Assessment of classification of project by pollution control board and bye laws / pre-requisites for setting up animal houses
The management of animal and experimental waste is a subject of considerable concern to public health and infection-control specialists, as well as the general public. It is a well known fact that in several types of health care activities, various types of hazardous and contagious materials are generated. Even though the consequences of discarding such waste carelessly are well known, it is only recently that adequate initiatives to manage this waste in a scientific manner are being taken in India. Unscientific disposal of such waste may lead to the transmission of communicable diseases such as gastro-enteric infections, respiratory infections, spreading through air water and direct human contact with the blood and infectious body fluids. These could be responsible for transmission of Hepatitis B, C, E and AIDS within the community. Health care professionals and the general public are at risk due to this. Diseases are spread by improper treatment and disposal of waste. Rag pickers expose themselves to diseases like Hepatitis B, Tetanus, Staphylococci, etc. while handling items like needles, surgical gloves, blood bags etc. The Bio-Medical Waste (Management and Handling) Rules; 1998 are conferred by section 6,8, 25 of the Environment (Protection) Act, 1986 (29 of 1986). Application: These rules apply to all persons who generate, collect, receive, store, transport, treat, dispose or handle bio-medical waste in any form. Biomedical waste means any waste, which is generated during the diagnosis, treatment or immunization of human beings or animals or in research activities pertaining thereto or in the production or testing of biologicals, means
2010
Confidential
88
KIPDC
any preparation made from organisms or micro-organisms or product of metabolism and biochemical reactions intended for use in the diagnosis, immunization or the treatment of human beings or animals or in research activities pertaining thereto These Rules will apply to all institutions generating biomedical waste which includes hospitals, nursing homes, clinics, dispensaries, veterinary hospital, animal house, research and pathological lab, and Blood Bank etc., generating biomedical waste. The Biomedical Waste (Management and Handling) Rules 1998, explicitly state that waste handling and treatment facilities shall have to be established within stipulated deadlines or earlier, for all waste generating establishments.
2010
Confidential
89
KIPDC
2010
Confidential
90
KIPDC
2010
Confidential
91
KIPDC
Through the course of the study it has been found that an animal house is a profitable venture in India, with scope of expansion and increased revenue opportunities in the future. As research activities increase within the country, and as India emerges as a preferred destination for outsourced research from international companies, the market for animal houses is expected to increase. On the basis of the findings in the study, Frost & Sullivan recommends the setting up of an animal house in Bangalore, Karnataka.
Rats/Mice 5000
Canines 40
2010
Confidential
92
KIPDC
Phase I The highest demand in the present Indian market for studies is for rats and mice. We recommend the animal house to concentrate on a rats and mice facility housing 5,000 animals. The facility can also house rabbits and guinea pigs, which are higher revenue earning, though lower in demand. Thus a facility housing 60 guinea pics and 30 rabbits can also be considered. Phase II The facility can be expanded to accommodate additional animals and strains, as per the demand from existing customers. Phase III Typically, as molecules are proven effective, their safety needs to be tested on large animals. Indian companies who are conducting tests on small animals will need to do so on large animals as well. Since outsouring such studies to international market may not always be feasible, a trusted Indian organization will be the next choice. Thus, as per demand the facility can expand to contain canines. Note: Primate Facilities are still rare in India, and need a higher regulatory compliance, as well as suffer from low demand. Hence, it is not suggested to set up a primate facility within 5 years from initiation of the animal house.
Facility Infrastructure
To ensure a continual revenue stream over a period of 10 years or more, we recommend the animal house to be AAALAC approvable. The facility may not immediately undergo a AAALAC accreditation, which is expensive and has stringent requirements. However, after a few years and a stable revenue source, the animal house can undertake a AAALAC accreditation, which will then enable it to source projects for US FDA or EMEA submissions. This will impact the revenues of the animal house.
2010
Confidential
93
KIPDC
Business Model
The suggested business model for the animal house will be to: a. supply animals to other animal houses across the country b. act as a center for toxicology studies on animals
Most Pharma companies have their own animal houses which are used for studies and in which they breed animals for their own requirements. However, they do not always have enough animals to service their requirements. Also, many companies prefer to buy animals for studies from independent animal houses, as this reduced their operational costs.
As the number of preclinical molecules increase, the number of toxicology tests to be performed also increase. The private animal houses of Pharma companies may not be able to handle the increased load, and it will be unfeasible for them to expand their facilities to cater to this requirement. In this phase it is expected by Frost & Sullivan that they will outsource their studies to CROs and animal houses who they feel are competent.
Frost & Sullivan strongly feels that over time it will be more feasible for companies to outsource their study requirements to animal houses than CROs because of the following factors: a. availability of animals within the same premises b. business focus on animal supply and studies, thus ensuring competence in the field c. cost competitiveness as compared to a CRO, where overheads for managing an animal house will be higher
2010
Confidential
94
KIPDC
b) Development of own strains which can then be sold to animal houses across the country and also outside the country c) Increased shared area, and hence reduced land wastage (common areas like gardening can be shared) d) Forward integration of an animal house into research and development The research center should act independently from the animal house, and not b e involved in the day to day activities of the animal house. This will ensure that Pharma companies and CROs continue to use the animal house for their studies without fear of their material being shared with another research center. The research center will act only as a leverage to develop new strains of animals as well as a regular (captive) client for the animals from the animal house. In case of high demand, the labs of the research centre can be used by the animal house for conducting some of its studies, on a prior notice and confidential basis. Thus, Frost & Sullivan recommends an animal house in Bangalore, Karnataka with the following business model: 1. Animal Supply Animal House 2. Animal House which conducts toxicology studies for Pharma companies and CROs 3. Animal House which has an independent research facility in the adjoining premises, ensuring a captive requirement and a source for new strain development (Optional) Frost & Sullivan suggests a further study to test a business model which also has an adjoining research center, and also analyse its effect on the business from Pharma company and CROs towards conducting of studies.
2010
Confidential
95
KIPDC
The animal house should be operated by personnel experienced in the animal house business. Since the animal house is recommended to be AAALAC complaint, the administration should also be well versed in the requirements of international regulations for Pharma and Biotech. It is suggested that the animal house be managed by a private entity, with associations in the Pharma and Biotech industry. This will ensure a regular flow of revenues from the initial year of setting up of the animal house. Since the land is owned by the Government of Karnataka, this will assist in compliance with the factors outlined for site selection. However, the government is not expected to have the prior experience and dedicated capability to ensure revenues from the animal house. It is therefore recommended that the government set up the animal house and hand over its operational activity to a bottom line generating private enterprise. Thus, a public-private-partnership (PPP) model is suggested.
Land Requirement
The suggested facility should be allocated 2 acres of land, keeping in mind scope of further expansion. If the option of research centre is also considered, land estimations will have to be re-considered.
Expenditure
The setting up of a AAALAC compliant animal house which houses 5,000 small animals is expected to cost at least INR 14cr apart from the cost of land. Apart from the above, a yearly running cost of INR 2.5 cr will be needed. This cost may be recovered within the second year of operations and thereafter be funded by the animal house itself.
2010
Confidential
96
KIPDC
2010
Confidential
97
KIPDC
ErbB2: In addition to ErbB2 role in breast cancer and cardiomyopathy, these mice also provide a model for the study of treatments for the loss of motor and sensory neurons. VgEcR-RXR: A modified ecdysone receptor (VgEcR) and the retinoid X receptor (RXR) transgenic mouse serves as a system for examiing ecdysone-regulated gene expression in mammalian cells with implications for neuronal function, lipid metabolism, signaling, cell cycle regulation, embryonic development, cancer and apoptosis. GIST: This gastro-intestinal stromal tumor knock-in model with a mutation in the kit gene initially identified in sporadic gastrointestinal stromal tumors. This model may be used to examine the functional significance of Kit and for pre-clinical validation of novel gastrointestinal stromal tumor therapies. PMS-2: Mutations in the Pms2 DNA repair gene are responsible for many hereditary nonpolyposis colorectal cancers. Mice deficient in Pms-2 may be used for drug screening of tumorcidal drugs, in particular for lymphoma and colorectal cancers. Model system for effect of diet in a cancer predisposing background. SK3 transgenic: The SK3 overexpression model may be used to investigate mechanisms that influence cardiomyopathy that may result from current cancer terapies. Sk3 is involved in the regulation of vaascular tone and blood pressue; thus modulation of its activity may help prevent cardiac dysfunction.
2010
Confidential
98
KIPDC
Mice
Strain Weaning
129P2
Blood
Plasma/Se ra
2010
Confidential
99
KIPDC
Webstar NSA OF1 NMRI Hybrid Strains B6129S2F1 /OlaHsd Blood Plasma/Se ra
B6C3F1/Ola Hsd
Blood
Plasma/Se ra
B6F1/OlaHs d
Blood
Plasma/Se ra
NZBNZWF1 /OlaHsd Mutant Strains Albino C57BL/6 Weaning PostWeaning Retired Blood Plasma/Se ra
2010
Confidential
100
KIPDC
Wallerian Degenerati on
Tnfrsf6^Lpr
Congenic mouse
B10.A-H2^h4 C.B10-H2^b BALB/C An.N (I.B) Weaning PostWeaning Retired Blood Plasma/Se ra
2010
Confidential
101
KIPDC
Rat
Breed Strain CFY/NIN (I.B) Weaning Type PostWeaning Retired Blood Animal Products Plasma/Sera
PostWeaning
Retired Blood
Plasma/Sera
Inbred Rats
ACI
BDIX
Lewis LUDW PVG Winstar Furth Wistar Weaning Kyoto (I.B) PostWeaning Retired Blood Plasma/Sera
PostWeaning
Retired Blood
2010
Confidential
102
KIPDC
Outbred Rats
Lister Hooded ORGA Sprague Dawley (O.B) Weaning PostWeaning Retired Blood Plasma/Sera
Holtzman (O.B)
Weaning
PostWeaning
Retired Blood
Plasma/Sera
B6SJLF1/J
Blood
Plasma/Sera
NZBWF1/J
Blood
Plasma/Sera
Athymic Nude
Blood
Plasma/Sera
2010
Confidential
103
KIPDC
PostWeaning
Retired
Blood
Plasma/Sera
2010
Confidential
104
KIPDC
Species Rabbit
Dutch Flemish Giant Watanabe Hamster Golden (Syrian)(I.B) Weanin g PostWeanin g Retire d Bloo d Plasma/Se ra
Large Animals
Species Horse Breed Kathiawari Horses Type Animal Products whole serum, blood plasma
2010
Confidential
105
KIPDC
Marwari Horses
Monkey
Rhesus Macaques
chimpanzee s
Macaca fascicularis Cat Dog Beagles CPB whole serum, blood plasma tissue samples
HFR RCC Gerbils Mongolian Gerbil whole serum, blood plasma tissue samples
Albino
2010
Confidential
106
KIPDC
Sable mitt
2010
Confidential
107
KIPDC
The Indian Pharmaceutical Industry (formulations and bulk) grew at a CAGR of around 20% to around US$ 17 bn in 2007-2008
Current In the last 6 years period, exports which account for 47% of the total industry, grew at a CAGR of 27%; while the domestic market grew at a CAGR of 14% The formulation segment, which constitutes 17% of the total industry reported a CAGR of 17% while bulk drugs aided by exports grew at a CAGR of 28% Contract research a nascent industry in India 5 years ago grew at a significant rate Bulk drug production: $2.10 billion, with over 400 bulk drugs produced. Over 60,000 Formulations produced, in 60 therapeutic categories Capital investment: up 14.8% to $1.16 billion Employment: 5 million direct, 24 million indirect
Future The upward growth trend is expected to continue Expected CAGR for the Indian Pharmaceutical Industry (formulations and bulk) is expected to be 1415% and the industry is anticipated to reach US$ 50 bn by 2015-2016 Exports driven by contract research are expected to grow at a CAGR of 16.2% while the domestic market is expected to grow at 12.5%
2010
Confidential
108
KIPDC
2006 - Total industry size US$ 1.45 billion, 50% of which was exports
India was #11 in the world and # 3 in APAC in terms of number of biotech companies
The CAGR for the period of 2002-2006 was 49% for the industry as a whole, 50.5% for domestic sales and ~46% for exports
While Bio-Pharma is the biggest segment in terms of value and volume, the Bio-Agri and BioServices are the fastest growing segments
In Bio-Pharma the growth primarily stems from the manufacturing of biogenerics and vaccines
2010
Confidential
109
KIPDC
India BioClusters
2010
Confidential
110
KIPDC
2010
Confidential
111